OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics,today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Conference Call and Webcast
What: |
|
OmniAb conference call to discuss second quarter 2026 financial results and business updates |
|
|
|
Date: |
|
Thursday, August 6, 2026 |
|
|
|
Time: |
|
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
|
Phone: |
|
U.S. (833) 461-5787 |
|
|
International (585) 542-9983 |
|
|
Conference ID is 545137839 |
|
|
|
Webcast: |
|
Live and replay webcast of the call with slides will be available here. |
About OmniAb®
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
OmniAb, Inc.
investors@OmniAb.com
X@OmniAbTech
Alliance Advisors IR
Vivian Cervantes
vcervantes@allianceadvisors.com
(973) 873-7724
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716057438/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States